1652 logo

Fusen Pharmaceutical Company Limited Stock Price

SEHK:1652 Community·HK$931.5m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

1652 Share Price Performance

HK$1.26
1.00 (384.62%)
HK$1.26
1.00 (384.62%)
Price HK$1.26

1652 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Fair value with low risk.

3 Risks
1 Reward

Fusen Pharmaceutical Company Limited Key Details

CN¥273.4m

Revenue

CN¥163.6m

Cost of Revenue

CN¥109.8m

Gross Profit

CN¥121.6m

Other Expenses

-CN¥11.8m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.016
40.16%
-4.31%
83.9%
View Full Analysis

About 1652

Founded
2003
Employees
1045
CEO
Zhiming Cao
WebsiteView website
www.fusenyy.com

Fusen Pharmaceutical Company Limited, an investment holding company, researches and develops, manufactures, and sells pharmaceutical products in the People’s Republic of China. The company’s product portfolio includes Shuanghuanglian oral solutions and Shuanghuanglian injections; Sanhuang tablet; heat-clearing and detoxicating oral solutions; nicardipine hydrochloride injections; and other products. It also offers small and large volume injections, oral liquids, tablets, capsules, granules, traditional Chinese medicine extracts, and chemical synthesis. In addition, the company provides business management and consulting services; and engages in the sale of construction material and electricity. It offers its medicines for the treatment of heat-clearing and detoxification, cardiovascular and cerebrovascular, antihypertensive and hypoglycemic, tonifying, qi-regulating, anti-anemia, and antibacterial and anti-inflammatory. Fusen Pharmaceutical Company Limited was founded in 2003 and is headquartered in Nanyang, China.

Recent 1652 News & Updates

Recent updates

No updates